

1 **Effects of Antibiotic Interaction on Antimicrobial Resistance Development in Wastewater**

2 Indorica Sutradhar<sup>1</sup> Carly Ching<sup>1</sup>, Darash Desai<sup>1</sup>, Zachary Heins<sup>1,2</sup>, Ahmad S. Khalil<sup>1,2,3</sup> &  
3 Muhammad H. Zaman<sup>1,4\*</sup>

4 <sup>1</sup>Department of Biomedical Engineering, Boston University, Boston, MA 02215, US;

5 <sup>2</sup>Biological Design Center, Boston University, Boston, MA 02215, US;

6 <sup>3</sup>Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA 02115,  
7 US;

8 <sup>4</sup>Howard Hughes Medical Institute, Boston University, Boston, MA 02215, USA

9 \*Corresponding author: zaman@bu.edu

10 **Abstract**

11 While wastewater is understood to be a critically important reservoir of antimicrobial  
12 resistance due to the presence of multiple antibiotic residues from industrial and agricultural  
13 runoff, there is little known about the effects of antibiotic interactions in the wastewater on the  
14 development of resistance. We worked to fill this gap in quantitative understanding of antibiotic  
15 interaction in constant flow environments by experimentally monitoring *E. coli* populations  
16 under subinhibitory concentrations of combinations of antibiotics with synergistic, antagonistic,  
17 and additive interactions. We then used these results to expand our previously developed  
18 computational model to account for the complex effects of antibiotic interaction. We found that  
19 while *E. coli* populations grown in additively interacting antibiotic combinations grew  
20 predictably according to the previously developed model, those populations grown under  
21 synergistic and antagonistic antibiotic conditions exhibited significant differences from predicted  
22 behavior. *E. coli* populations grown in the condition with synergistically interacting antibiotics  
23 developed less resistance than predicted, indicating that synergistic antibiotics may have a  
24 suppressive effect on antimicrobial resistance development. Furthermore *E. coli* populations  
25 grown in the condition with antagonistically interacting antibiotics showed an antibiotic ratio-  
26 dependent development of resistance, suggesting that not only antibiotic interaction, but relative  
27 concentration is important in predicting resistance development. These results provide critical  
28 insight for quantitatively understanding the effects of antibiotic interactions in wastewater and  
29 provide a basis for future studies in modelling resistance in these environments.

## 30 **Importance**

31 Antimicrobial resistance (AMR) is a growing global threat to public health expected to impact 10  
32 million people by 2050, driving mortality rates globally and with a disproportionate effect on  
33 low- and middle- income countries. Communities in proximity to wastewater settings and  
34 environmentally contaminated surroundings are at particular risk due to resistance stemming  
35 from antibiotic residues from industrial and agricultural runoff. Currently, there is a limited  
36 quantitative and mechanistic understanding of the evolution of AMR in response to multiple  
37 interacting antibiotic residues in constant flow environments. Using an integrated computational  
38 and experimental methods, we find that interactions between antibiotic residues significantly  
39 affect the development of resistant bacterial populations.

## 40 Introduction

41 Antimicrobial resistance (AMR) is a rapidly evolving critical threat to global health with the  
42 potential to lead to financial losses of as much as \$100 trillion USD (1, 2). A recent systematic  
43 analysis of global AMR has predicted that there were an estimated 4.95 million deaths associated  
44 with bacterial AMR in 2019 (3). Contributing factors to AMR in human medicine (i.e.,  
45 prescription patterns, poor patient treatment adherence etc.) have been well documented (4–7);  
46 however, environmental distribution of antibiotics and its impact on AMR has received less  
47 attention (8, 9). Wastewater specifically has been shown to be a reservoir of resistant pathogens,  
48 often stemming from the antibiotic pollution present in runoff from industrial and agricultural  
49 sources (10). Furthermore, computational modeling of wastewater has shown that even low  
50 concentrations of antibiotic residues can lead to the development of AMR (11). This is  
51 particularly of concern in low-income communities which can often have open sewer systems  
52 and little access to wastewater treatment, putting them at particular risk for deadly drug-resistant  
53 outbreaks.

54 Previously, we have developed a computational model of resistance acquisition in continuous  
55 flow environments based on known mechanisms of bacterial growth and mutation as well as  
56 experimental validation (11). However, experimental validation of the model was limited to  
57 systems with only one antibiotic residue. The interaction between two or more antibiotics is of  
58 particular interest, with combination therapy used both clinically to increase treatment efficacy  
59 and lower the risk of AMR development as well as prophylactically in livestock to prevent  
60 infections from developing and spreading across these large animal populations. The interaction  
61 between two antibiotics from different classes have previously been shown to affect resistance  
62 acquisition (12). Synergy is the interaction of multiple drugs to have a greater killing action than  
63 the sum of their parts while antagonism is the interaction of multiple drugs to have reduced  
64 killing action than the sum of their parts. Drugs that do not interact, or in other words have the  
65 killing action equal to the sum of their parts are said to have an additive interaction. Interestingly,  
66 synergy between two antibiotics has also been shown to increase the likelihood of resistance  
67 population development at subtherapeutic doses (12). However, the effects of antibiotic  
68 interaction on the growth of resistant populations in wastewater settings has not previously been  
69 observed. Wastewater can often have many antibiotic residues present, which have the potential  
70 to interact with each other either synergistically or antagonistically. For example, antibiotic  
71 residues found in water sampled from hospital sewage in Sweden included the drugs  
72 doxycycline, erythromycin, and ciprofloxacin among others (13). This is of note because  
73 doxycycline and erythromycin are known to have a synergistic interaction, while doxycycline  
74 and ciprofloxacin are known to have an antagonistic interaction (12). Antimicrobials in  
75 combination often have different mechanisms of action, so it is possible that interactions between  
76 the multiple antibiotic residues in wastewater will have unique effects on the development of  
77 antimicrobial resistance. However, quantitative data on these effects of antibiotic interactions on  
78 AMR in wastewater is lacking. We aim to fill this critical gap in knowledge about the effects of  
79 antibiotic interactions on AMR in continuous flow environments such as wastewater through an  
80 iterative approach to computational modeling and experimental validation.

81

## 82 **Methods**

### 83 *Model Development*

84 The model used in this paper is based on a previously developed model of the growth of  
85 antibiotic resistant bacterial populations in wastewater that builds on prior studies and extends to  
86 incorporate a variety of critical inputs which can be broadly classified into bacterial parameters,  
87 environmental parameters and antibiotic parameters (11). Bacteria specific input factors include  
88 the growth rates of antibiotic susceptible and resistant strains and mutation rates in response to  
89 subinhibitory concentrations of antibiotic. The antibiotic specific inputs, such as bactericidal  
90 activity, allow for the study of the effects of antibiotic pollution on the development of  
91 resistance. Additionally, environmental inputs, including physical inflow and outflow rates and  
92 antibiotic residue concentrations, allow for the modelling of resistance development in a variety  
93 of settings of interest. Ordinary differential equations incorporating these input parameters were  
94 used to model an output of resistant bacterial populations over time, thus allowing for the  
95 prediction of resistant population development (Eq Set 1 and Table 1).

### 96 *Experimental Validation*

97 Experimental validation of the model was done using the eVOLVER system, which is an  
98 automated, highly flexible platform allowing for scalable continuous culture microbial growth  
99 and independent, precise and multiparameter control of growth conditions such as temperature  
100 and flow rate (14). Experiments were done with antibiotics which have been found to be present  
101 in wastewater with known interactions with one pair of antibiotics exhibiting additive interaction  
102 (12.5 mg/L Rifampicin + 4 mg/L Streptomycin), one pair of antibiotics exhibiting synergistic  
103 interaction (1.5 mg/L Doxycycline + 64 mg/L Erythromycin) and one pair of antibiotics  
104 exhibiting antagonistic interaction (1.5 mg/L Doxycycline + 0.0375 mg/L Ciprofloxacin) (12-13,  
105 15-17). Drug interactions were confirmed using checkerboard assays and calculating fractional  
106 inhibitory concentration (FIC) values as described in Bellio et al. where combinations with an  
107 FIC less than 0.5 were considered synergistic, those with an FIC greater than 4 were considered  
108 antagonistic and those with an FIC between 0.5 and 4 were considered to have an additive  
109 interaction (18). Experiments were initialized with inoculation of LB media with *E. coli*  
110 MG1655 in static conditions at 37°C. Then, inflow and outflow of the antibiotic-containing LB  
111 media at two concentration combinations was started. During the course of the experiment, each  
112 culture condition was sampled daily, and the concentrations of total bacteria and resistant  
113 bacteria were calculated through plating on drug-free and selective LB agar containing 8X MIC  
114 Drug A and/or 8X MIC Drug B respectively.

115

## 116 **Results**

117

### 118 *Drugs with Additive Interaction Develop Resistance Predictably*

119 The first antibiotic combination tested was Rifampicin and Streptomycin at half of their  
120 respective MICs (12.5 mg/L Rifampicin + 4 mg/L Streptomycin). Checkerboard assays  
121 confirmed an FIC of 1 indicating additive interaction between these two drugs. Model prediction  
122 was made based on previously determined parameter values from eVOLVER experiments with  
123 each drug in isolation. The experimental results with the eVOLVER qualitatively verified the  
124 model prediction with dominant susceptible and Rifampicin-resistant populations as well as a  
125 significant population of bacteria resistant to both Rifampicin and Streptomycin (Figure 1).  
126 While a population of bacteria resistant to Streptomycin only was not observed experimentally,  
127 this may be due to the transient nature of this population not being captured in the sampling  
128 frequency. This confirmed the assumption that antibiotics with no interaction behave predictably  
129 in combination.

### 130 *Synergistic Interaction Show Lower than Expected Resistance*

131 The second antibiotic combination tested was Doxycycline and Erythromycin, which in addition  
132 to have been observed in wastewater sampling, have also previously found to interact  
133 synergistically (13, 17). Checkerboard assays confirmed an FIC of 0.375 indicating synergistic  
134 interaction. Initial model prediction was made based on previously determined parameter values  
135 from eVOLVER experiments with each drug in isolation and assuming no effect from antibiotic  
136 interaction, showing dominant Doxycycline resistant and combination resistant populations  
137 (Figure 2a). Experimental results showed lower levels of resistance than predicted, particularly in  
138 the bacterial population resistant to both drugs (Figure 2b). In order to reproduce the  
139 experimental behavior, a synergy parameter, equal to the FIC value for the given antibiotic  
140 combination, was then introduced as a multiplying factor to the mutation parameter to account  
141 for reduced resistance levels (Eq set 1). The results of this change are shown in Figure 2c. These  
142 results suggest that synergy may have a suppressive effect on the development of resistance due  
143 to a decrease in the mutation rates proportional to the degree of synergy. This is of particular  
144 interest because previous studies done in non-flow conditions saw increased resistance in  
145 synergistic conditions compared to antibiotics with no interaction, indicating that environments  
146 with constant flow cannot be adequately predicted with only data from standard non-flow culture  
147 conditions (17).

### 148 *Drugs with Antagonistic Interaction Exhibit Ratio-Dependent Resistance Development*

149 The third antibiotic combination tested was Doxycycline and Ciprofloxacin which have been  
150 observed as residues in wastewater samples and have previously found to interact  
151 antagonistically (13, 17). Checkerboard assays confirmed an FIC of 4 indicating antagonistic  
152 interaction. Initial experimental results showed lower levels of resistance than predicted, and no  
153 observable bacterial population resistant to both drugs (Figure 3a). However, previous studies  
154 indicated that unlike in additive and synergistic combinations, resistance development in

155 Doxycycline and Ciprofloxacin combinations may differ depending on the relative  
156 concentrations of the two (17). Additional experiments were conducted with differing ratios of  
157 Doxycycline and Ciprofloxacin (0.9 MIC Dox: 0.1 MIC Cip; 0.7 MIC Dox: 0.3 MIC Cip; 0.5  
158 MIC Dox: 0.5 MIC Cip; 0.3 MIC Dox: 0.7 MIC Cip; 0.1 MIC Dox: 0.9 MIC Cip). These  
159 experiments found an antibiotic-ratio dependent effect. Several changes were made to the  
160 previous model to account for the ratio dependency of the resistant population behavior (Table  
161 2). First, the growth term was adjusted to include an antibiotic concentration dependent growth  
162 rate function rather than a constant growth rate parameter. Additionally, the bacterial killing rate  
163 parameter was similarly adjusted to include a resistant population-dependent killing rate function  
164 rather than a constant killing rate. The results of the adjusted model for the 50% MIC Dox and  
165 50% MIC Cip condition are shown in Figure 3b, demonstrating the model's ability to capture the  
166 dominant susceptible population as well as the lower Doxycycline resistant population and the  
167 absence of the combination resistant population as seen in Figure 3a.

168 This adjusted model was able to capture the relative behaviors of the different resistant  
169 populations for differing ratios of Dox and Cip, notably the transient Doxycycline-resistant  
170 population giving way to the combination resistant population (Figure 4). Furthermore, the  
171 model successfully captures the increased time the Doxycycline-resistant population was present  
172 in the condition with 0.9X MIC Dox (Figures 4c-d) compared to the condition with 0.7X MIC  
173 Dox (Figures 4a-b). However, it failed to capture the sustained drug-susceptible population in  
174 the high Cip concentration conditions. We hypothesize that this may be due to a separation of the  
175 drug susceptible populations from the resistant population between the planktonic bacteria and  
176 the bacteria in the biofilm that form at walls of the eVOLVER vials. Biofilm has been seen to  
177 have different resistance profiles than planktonic bacteria which may explain why the model,  
178 which only accounts for the bacteria under constant flow conditions, does not fully capture the  
179 susceptible population (19). Though the current model is limited in its ability to model bacteria  
180 in biofilm, it still succeeds in being able to predict the resistance development occurring in the  
181 continuous liquid culture. Thus, it still can have use as a predictive tool for understanding AMR  
182 in wastewater.

## 183 **Discussion and Conclusions**

184 Overall, through our integrated computational and experimental approach, we were able  
185 to model the development of antibiotic resistance in response to subinhibitory combinations of  
186 antibiotics exhibiting additive, synergistic and antagonistic interactions. We demonstrated *E. coli*  
187 populations grown in additively interacting antibiotic combinations grew predictably according  
188 to the previously developed model. This confirmed our assumption that in the absence of  
189 antibiotic interaction, resistance to each antibiotic will develop independently. We also found  
190 that *E. coli* populations grown under synergistic and antagonistic antibiotic conditions exhibited  
191 significant differences from predicted behavior. *E. coli* populations growing in subinhibitory  
192 concentrations of synergistically interacting antibiotics showed the development of less  
193 resistance than predicted. Interestingly, this indicated that synergistic antibiotics have a  
194 suppressive effect on antimicrobial resistance development in continuous flow conditions. This is

195 in contrast to previous studies in non-flow conditions which found that synergy increased  
196 resistance acquisition (12, 20). Thus, our novel finding suggests that differing flow conditions  
197 significantly alter resistance acquisition patterns and studies in continuous flow conditions are  
198 necessary for understanding environments like wastewater. Additionally, we found that *E. coli*  
199 populations grown with antagonistically interacting antibiotics showed an antibiotic ratio-  
200 dependent development of resistance. This behavior has previously been observed in non-flow  
201 conditions, though only with single-resistant populations (17). Our studies further this finding to  
202 multi-resistant populations and also find that not only antibiotic interaction, but relative  
203 concentration is important in predicting resistance development in continuous flow  
204 environments.

205         Though we have been able to draw a number of conclusions about the effects of  
206 antibiotic interaction on resistance development in wastewater, we note that our studies do have  
207 limitations. Primarily, we only studied a limited number of antibiotic combinations and as such  
208 cannot conclude the effects of all antibiotic interactions. Future studies investigating a wider  
209 array of antibiotics could elucidate further findings on specific combinations in constant flow  
210 conditions. Additional studies looking at three or more antibiotics in combination with varying  
211 interactions or media conditions better approximating wastewater than the LB broth used here  
212 would also be a step forward in modelling the types of complex conditions that would be found  
213 in wastewater. Another major area of interest in developing the model would be to further  
214 integrate the role of biofilm in resistance development. While biofilm has been observed in  
215 samples both up- and downstream from wastewater treatment plants and is a known  
216 environmental reservoir of resistance, there is limited quantitative understanding of how this  
217 resistance develops, particularly in response to antibiotic residues present in wastewater (21, 22).  
218 In order to develop quantitative models of resistance development in wastewater incorporating  
219 both planktonic bacteria and biofilm, experimental methods for controllably maintaining both  
220 populations in continuous flow conditions will need to be developed.

221         Despite these limitations, experimental validation demonstrated our ability to model  
222 resistance development in subinhibitory antibiotic concentrations of antibiotics with varying  
223 interactions. We were able to determine that synergistic interaction have a suppressive effect on  
224 resistance development. Additionally, more complex resistance development patterns were  
225 observed in the case of antagonistic interaction where we found an antibiotic ratio-dependent  
226 behavior. This has important implications for understanding the effects of industrial and  
227 agricultural antibiotic runoff in wastewater and determining acceptable antibiotic concentrations  
228 and combinations when treating wastewater. These findings can be used as a basis for public  
229 health policy makers and the developed model can be utilized to predict resistant population  
230 emergence in different sewage and wastewater conditions where multiple antibiotic residues may  
231 be present.

232

233 **Author Contributions**

234 I. Sutradhar designed the model, conducted experiments, and analyzed the data. C. Ching and D.  
235 Desai provided guidance on model design and verification. A. Khalil provided facilities for  
236 experimental work with the eVOLVER and Z. Heins provided assistance on experimental  
237 design. I. Sutradhar and M. H. Zaman wrote the article.

238

239 **Conflicts of Interest**

240 ASK is a co-founder of Fynch Biosciences, a manufacturer of eVOLVER hardware.

241

242 **Acknowledgements**

243 This research was supported in part by the National Institutes of Health (NIH) training grant at  
244 Boston University, T32 EB006359 (to I. S.) and the NIH grant R01AI171100 to A.S.K. A.S.K.  
245 also acknowledges funding from a NIH Director's New Innovator Award (DP2AI131083) and a  
246 Department of Defense Vannevar Bush Faculty Fellowship (N00014-20-1-2825). The content is  
247 solely the responsibility of the authors and does not necessarily represent the official views of the  
248 National Institutes of Health.

249

## 250 **References**

- 251 1. The Center for Disease Dynamics Economics and Policy. Antibiotic Resistance:  
252 Resistance Map.
- 253 2. Gupta, S. & Nayak, R. Dry antibiotic pipeline: Regulatory bottlenecks and regulatory  
254 reforms. *J. Pharmacol. Pharmacother.* **5**, 4–7 (2014).
- 255 3. O’Neill, J. *Antimicrobial Resistance: Tackling a crisis for the health and wealth of*  
256 *nations*. (2014).
- 257 4. Costelloe, C., Metcalfe, C., Lovering, A., Mant, D. & Hay, A. D. Effect of antibiotic  
258 prescribing in primary care on antimicrobial resistance in individual patients: systematic  
259 review and meta-analysis. *Bmj* **340**, c2096–c2096 (2010).
- 260 5. Weis, S. E., Slocum, P., Blais, F., King, B., Nunn, M., Matney, B., Gomez, E. &  
261 Foresman, B. The Effect of Directly Observed Therapy on the Rates of Drug Resistance  
262 and Relapse in Tuberculosis. *N. Engl. J. Med.* **330**, 1179–1184 (1994).
- 263 6. Angulo, F. J., Baker, N. L., Olsen, S. J., Anderson, A. & Barrett, T. J. Antimicrobial use  
264 in agriculture: Controlling the transfer of antimicrobial resistance to humans. *Semin.*  
265 *Pediatr. Infect. Dis.* **15**, 78–85 (2004).
- 266 7. Perez, K. K., Olsen, R. J., Musick, W. L., Cernoch, P. L., Davis, J. R., Peterson, L. E. &  
267 Musser, J. M. Integrating rapid diagnostics and antimicrobial stewardship improves  
268 outcomes in patients with antibiotic-resistant Gram-negative bacteremia. *J. Infect.* **69**,  
269 216–225 (2014).
- 270 8. The Lancet Planetary Health. The natural environment and emergence of antibiotic  
271 resistance. *The Lancet Planetary Health* vol. 2 e2–e3 (2018).
- 272 9. Van Boeckel, T. P., Glennon, E. E., Chen, D., Gilbert, M., Robinson, T. P., Grenfell, B.  
273 T., Levin, S. A., Bonhoeffer, S. & Laxminarayan, R. Reducing antimicrobial use in food  
274 animals. *Science* vol. 357 1350–1352 (2017).
- 275 10. Nadimpalli, M. L., Marks, S. J., Montealegre, M. C., Gilman, R. H., Pajuelo, M. J., Saito,  
276 M., Tsukayama, P., Njenga, S. M., Kiiru, J., Swarthout, J., Islam, M. A., Julian, T. R. &  
277 Pickering, A. J. Urban informal settlements as hotspots of antimicrobial resistance and  
278 the need to curb environmental transmission. *Nat. Microbiol.* **5**, 787–795 (2020).
- 279 11. Sutradhar, I., Ching, C., Desai, D., Suprenant, M., Briars, E., Heins, Z., Khalil, A. S., &  
280 Zaman, M. H. (2020). Computational model to quantify the growth of antibiotic resistant  
281 bacteria in wastewater. *mSystems*. <https://doi.org/10.1101/2020.10.09.333575>
- 282 12. Singh, N., & Yeh, P. J. (2017). Suppressive drug combinations and their potential to  
283 combat antibiotic resistance. *The Journal of antibiotics*, 70(11), 1033–1042.  
284 <https://doi.org/10.1038/ja.2017.102>
- 285 13. Lindberg, R. Determination of Antibiotics in the Swedish Environment with Emphasis on  
286 Sewage Treatment Plants (2006)

- 287 14. Wong, B. G., Mancuso, C. P., Kiriakov, S., Bashor, C. J. and A. S. Khalil. 2018. Precise,  
288 automated control of conditions for high-throughput growth of yeast and bacteria with  
289 eVOLVER. *Nat. Biotechnol.* 36, 614–623.
- 290 15. Khan AU, Shah F, Khan RA, Ismail B, Khan AM, Muhammad H. Preconcentration of  
291 rifampicin prior to its efficient spectroscopic determination in the wastewater samples  
292 based on a nonionic surfactant. *Turk J Chem.* 2021 Aug 27;45(4):1201-1209. doi:  
293 10.3906/kim-2102-28. PMID: 34707444; PMCID: PMC8517608.
- 294 16. Deng Y, Zhang Y, Gao Y, Li D, Liu R, Liu M, Zhang H, Hu B, Yu T, and Yang M.  
295 Microbial Community Compositional Analysis for Series Reactors Treating High Level  
296 Antibiotic Wastewater. *Environmental Science & Technology* 2012 46 (2), 795-801.  
297 DOI: 10.1021/es2025998
- 298 17. Chait, R., Craney, A. & Kishony, R. Antibiotic interactions that select against resistance.  
299 *Nature* 446, 668–671 (2007). <https://doi.org/10.1038/nature05685>
- 300 18. Bellio, P., Fagnani, L., Nazzicone, L. & Celenza, G. New and simplified method for drug  
301 combination studies by checkerboard assay. *MethodsX* 8, 101543 (2021).
- 302 19. Sharma, D., Misba, L. & Khan, A.U. Antibiotics versus biofilm: an emerging  
303 battleground in microbial communities. *Antimicrob Resist Infect Control* 8, 76 (2019).  
304 <https://doi.org/10.1186/s13756-019-0533-3>
- 305 20. Michel, J. B., Yeh, P. J., Chait, R., Moellering, R. C. & Kishony, R. Drug interactions  
306 modulate the potential for evolution of resistance. *Proc. Natl. Acad. Sci. U. S. A.* **105**,  
307 14918–14923 (2008).
- 308 21. Tamminen M, Spaak J, Tlili A, Eggen R, Stamm C, Räsänen K, Wastewater constituents  
309 impact biofilm microbial community in receiving streams, *Science of The Total*  
310 *Environment*, Volume 807, Part 3, 2022, 151080,  
311 <https://doi.org/10.1016/j.scitotenv.2021.151080>.
- 312 22. Flores-Vargas G, Bergsveinson J, Lawrence JR, Korber DR. Environmental Biofilms as  
313 Reservoirs for Antimicrobial Resistance. *Front Microbiol.* 2021 Dec 13;12:766242. doi:  
314 10.3389/fmicb.2021.766242. PMID: 34970233; PMCID: PMC8713029.

315 **Tables and Equations**

$$\begin{aligned}
 1) \quad & \frac{dC_1}{dt} = E_1 - k_e C_1 \\
 2) \quad & \frac{dC_2}{dt} = E_2 - k_e C_2 \\
 3) \quad & \frac{dS}{dt} = \alpha_S \left(1 - \frac{R_m + R_1 + R_2 + S}{N_{max}}\right) S + g_S - k_T S - syn * \delta_{max,1} \left(\frac{C_1}{C_1 + C_S^{50}}\right) S - \\
 & \quad syn * \delta_{max,2} \left(\frac{C_2}{C_2 + C_S^{50}}\right) S \\
 4) \quad & \frac{dR_m}{dt} = \alpha_R \left(1 - \frac{R_m + R_1 + R_2 + S}{N_{max}}\right) R_m + g_{Rm} - k_T R_m - syn * \delta_{max,1} \left(\frac{C_1}{C_1 + C_{R,1}^{50}}\right) R_m - \\
 & \quad syn * \delta_{max,2} \left(\frac{C_2}{C_2 + C_{R,2}^{50}}\right) R_m + syn * m_T(C_1, C_2) S + R_1 m_2(C_2) + R_2 m_1(C_1) \\
 5) \quad & \frac{dR_1}{dt} = \alpha_{R,1} \left(1 - \frac{R_m + R_1 + R_2 + S}{N_{max}}\right) R_1 + g_{R1} - k_T R_1 - syn * \delta_{max,1} \left(\frac{C_1}{C_1 + C_{R,1}^{50}}\right) R_1 - \\
 & \quad syn * \delta_{max,2} \left(\frac{C_2}{C_2 + C_S^{50}}\right) R_1 + m_1(C_1) S \\
 6) \quad & \frac{dR_2}{dt} = \alpha_{R,2} \left(1 - \frac{R_m + R_1 + R_2 + S}{N_{max}}\right) R_2 + g_{R2} - k_T R_2 - syn * \delta_{max,1} \left(\frac{C_1}{C_1 + C_S^{50}}\right) R_2 - \\
 & \quad syn * \delta_{max,2} \left(\frac{C_2}{C_2 + C_{R,2}^{50}}\right) R_2 + m_2(C_2) S
 \end{aligned}$$

316 **Eq Set 1.** Sensitive and resistant populations under selective pressure from antimicrobial  
 317 combination therapy, adapted from Sutradhar et al. 2021<sup>11</sup>

318

<b>Variable</b>	<b>Definitions</b>
$C_1$	Antibiotic 1 Concentration (ug/mL)
$C_2$	Antibiotic 2 Concentration (ug/mL)
$S$	Susceptible (cells)
$R_m$	Resistant to both Antibiotic 1 and Antibiotic 2 from Chromosomal Mutation (cells)
$R_1$	Resistant to only Antibiotic 1 from Chromosomal Mutation (cells)
$R_2$	Resistant to only Antibiotic 2 from Chromosomal Mutation (cells)
$E$	Environmental Concentration of Antibiotic((ug/mL)/hr)
$syn$	Synergy Parameter (non-dimensional)
$k_e$	Antibiotic Clearance (1/hr)
$\alpha_S$	Growth Rate of Susceptible Bacteria (1/hr)
$\alpha_{Rm}$	Growth Rate of Bacteria Resistant from Mutation (1/hr)
$N_{max}$	Carrying Capacity (cells/mL)
$g_S, g_{Rm},$ $g_{R1}, g_{R2}, g_{Rp}$	Bacterial Influx Rates (cells/hr)
$k_T$	Bacterial Efflux Rate (1/hr)
$\delta_{max,1}, \delta_{max,2}$	Bacterial Killing Rate in Response to Antibiotic 1 and Antibiotic 2 (1/hr)
$C_S^{50}, C_{R,1}^{50},$ $C_{R,2}^{50}$	Antibiotic Concentration where the Killing Action is Half its Maximum Value (ug/mL)
$m_1(C_1)$	Mutation Frequency under Antibiotic 1 (1/hr)
$m_2(C_2)$	Mutation Frequency under Antibiotic 2 (1/hr)

319

320 **Table 1.** Model variables and definitions

321

Base Model	Adjusted Model for Antagonism
<p>Growth Term:</p> $\alpha_{R,2} * \left(1 - \frac{R_m + R_1 + R_2 + S}{N_{max}}\right) R_2$	<p>Growth Term: <math>\alpha_{R,2}(MIC1, MIC2) * \left(1 - \frac{R_m + R_1 + R_2 + S}{N_{max}}\right) R_2</math></p> <p>Where : <math>\alpha_{R,2}(MIC1, MIC2) = \alpha_{R,2} * sup1 * \left(\frac{MIC1}{MIC2}\right)</math></p>
<p>Bacterial Killing from Dox:</p> $syn * \delta_{max,2} \left(\frac{C_2}{C_2 + C_{R,2}^{50}}\right) R_2$	<p>Bacterial Killing from Dox: <math>syn * \delta_{max,2}(R_1, R_2) * \left(\frac{C_2}{C_2 + C_{R,2}^{50}}\right) R_2</math></p> <p>Where: <math>\delta_{max,2}(R_1, R_2) = \delta_{max,2} * sup2 * \left(\frac{R_1}{R_2}\right)</math></p>


322

Parameter	Description
$sup1$	Cip Suppression Variable 1
$sup2$	Cip Suppression Variable 2
$\alpha_S$	Growth Rate of Susceptible Bacteria (1/hr)
$\alpha_R,$ $\alpha_{R,1}, \alpha_{R,2}$	Growth Rate of Bacteria Resistant from Mutation (1/hr)
$N_{max}$	Carrying Capacity (cells/mL)
$MIC1$	MIC in response to Cip
$MIC2$	MIC in response to Dox
$\delta_{max,1},$ $\delta_{max,2}$	Bacterial Killing Rate in Response to Antibiotic 1 and Antibiotic 2 (1/hr)

323 **Table 2:** Model adjustment for antibiotic-ratio dependent antagonistic behavior

324


325 **Figures**




326 **Figure 1: a.)** Experimental results for combination of 0.5X MIC Rifampicin and 0.5X MIC  
327 Streptomycin in eVOLVER. **b.)** Model prediction for combination of 0.5X MIC Rifampicin and  
328 0.5X MIC Streptomycin in eVOLVER

329

330




331



332

333 **Figure 2:** a.) Model prediction for combination of 0.5X MIC Doxycycline and 0.5X MIC  
334 Erythromycin in eVOLVER in absence of interaction b.) eVOLVER results for combination of  
335 0.5 MIC Doxycycline and 0.5 MIC Erythromycin c.) Model prediction for combination of 0.5X  
336 MIC Doxycycline and 0.5X MIC Erythromycin in eVOLVER with synergy parameter


337



338 **Figure 3: a.)** eVOLVER results for combination of 0.5 MIC Doxycycline and 0.5 MIC  
339 Ciprofloxacin **b.)** Model prediction for combination of 0.5 MIC Doxycycline and 0.5 MIC  
340 Ciprofloxacin in eVOLVER with antibiotic ratio dependent model adjustments

341

342



343 **Figure 4:** a.) eVOLVER results for combination of 0.3 MIC Doxycycline and 0.7 MIC  
344 Ciprofloxacin in eVOLVER in absence of interaction b.) Model prediction for combination of  
345 0.3 MIC Doxycycline and 0.7 MIC Ciprofloxacin in eVOLVER with antibiotic ratio dependent  
346 model adjustments c.) eVOLVER results for combination of 0.1 MIC Doxycycline and 0.9 MIC  
347 Ciprofloxacin in eVOLVER in absence of interaction d.) Model prediction for combination of  
348 0.1 MIC Doxycycline and 0.9 MIC Ciprofloxacin in eVOLVER with antibiotic ratio dependent  
349 model adjustments